Julie Stein Deutsch

6PUBLICATIONS
63CO-AUTHORS
Predictive and prognostic markersTumour immunologyMolecular targetsAllergyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 12, 2026
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer.

|Sep 08, 2025
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.

Joshua E Reuss, Paul K Lee, Reza J Mehran

|Nov 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.

Samuel Rosner, Sydney Connor, Khaled Sanber

|Apr 21, 2022
Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD-1 therapy resemble acute graft versus host disease more than lichen planus.

Guillermo E Almodovar Cruz, Genevieve Kaunitz, Julie E Stein

|Jun 11, 2021
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.

Sneha Berry, Nicolas A Giraldo, Benjamin F Green

|Apr 15, 2018
Anti-TNF therapy-induced lupus erythematosus-like syndrome in a patient treated with adalimumab for cutaneous psoriasis.

Julie E Stein, Jeffrey Patterson-Fortin, Benjamin E Bodnar

Pageof 1

Frequent Collaborators

5 joint publications

Janis Taube

4 joint publications

Tricia R Cottrell

3 joint publications

Drew M Pardoll

2 joint publications

Jonathan Spicer